招银国际表示，在2025年BD交易爆发式增长基础上，2026年初已连续有多项授权落地，反映行业出海 景气度持续高企，未来中国创新药有望凭借早期临床数据获得更高交易价值。展望2026年，创新药出海 趋势长期或将延续，后续应重点关注已出海管线的临床进展与数据兑现的核心催化。 据悉，恒生创新药ETF（520500）通过QDII机制投资31家港股创新药龙头企业，覆盖行业研发前沿与商 业化核心力量，主要聚焦于生物制药、化学制药及原料药等中上游创新药核心领域，集结了一众研发实 力强劲、具备发展潜力的创新药行业翘楚。 尽管今日早盘（26/1/26）创新药板块有所回调，但市场交投依然保持活跃。目前全市场仅有的跟踪恒 生创新药指数的产品——恒生创新药ETF（520500）2026年以来日均成交额达6.24亿元，基金规模、份 额分别达21.02亿元、12.74亿份，显示资金关注度较高。 行业层面，中国创新药出海势头强劲。医药魔方NextPharma数据库显示，2025年中国创新药共完成157 起BD出海授权交易，交易总额为1356.55亿美元，其中首付款70亿美元，这三项关键数据均创下历史新 高。值得关注的是，在2025年全球L ...

尽管今日早盘（26/1/26）创新药板块有所回调，但市场交投依然保持活跃。目前全市场仅有的跟踪恒 生创新药指数的产品——恒生创新药ETF（520500）2026年以来日均成交额达6.24亿元，基金规模、份 额分别达21.02亿元、12.74亿份，显示资金关注度较高。 （数据来源：交易所、Wind，数据截至26/1/23） 行业层面，中国创新药出海势头强劲。医药魔方NextPharma数据库显示，2025年中国创新药共完成157 起BD出海授权交易，交易总额为1356.55亿美元，其中首付款70亿美元，这三项关键数据均创下历史新 高。值得关注的是，在2025年全球License-out交易总额前十名中，有八项来自中国；总交易额超百亿美 元的4起交易中，中国占据3席。2025年中国创新药BD交易总额已占全球49%，首次超越美国。 （消息来源：36氪-狂揽1357亿美元！谁是2025中国创新药出海"最贵"十单？-26/1/26） 政策环境亦提供有力支持。商务部等九部门联合发布《关于促进药品零售行业高质量发展的意见》，明 确提出优化药品营销体系，鼓励创新药进入零售药店销售渠道，助力市场拓展。 （商务部-商务部等9部门 ...

Group 1 - The total trading volume of the Shanghai and Shenzhen Stock Connect today reached 295.9 billion, with Kweichow Moutai and CATL leading in individual stock trading volume [1][2] - The electronic sector saw the highest net inflow of funds, while the mechanical equipment sector experienced the largest net outflow [6][5] - The top ten stocks by trading volume on the Shanghai Stock Connect included Kweichow Moutai at 32.39 billion, while on the Shenzhen Stock Connect, CATL led with 50.67 billion [3][4] Group 2 - The Hong Kong Stock Connect Technology ETF (159101) saw a significant trading volume increase of 378% compared to the previous trading day [10] - The top ten ETFs by trading volume included the A500 ETF Huatai Baichuan (563360) at 158.67 billion, followed closely by the A500 ETF Fund (512050) at 156.67 billion [9] - The top ten stocks with the highest net inflow of funds included Shenghong Technology at 19.67 billion and Kweichow Moutai at 9.75 billion [7][12] Group 3 - The AI application concept stock BlueFocus achieved a two-day consecutive increase, attracting 186 million from two institutions, while it also received 156 million from the Shenzhen Stock Connect [13][15] - The lithium battery concept stocks performed strongly, with Tianji Co. receiving significant purchases from multiple leading funds [15][14] - The trading activity of quantitative funds was notably high, with several firms making substantial purchases in various stocks [16]

Market Performance - The A-share market experienced a nine-day rally, with the Shanghai Composite Index rising by 0.31% and the Shenzhen Component Index increasing by 0.03% [1] - The ChiNext Index fell by 0.32%, while the North China 50 Index rose by 0.11% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1.4078 trillion yuan, a decrease of 57.8 billion yuan compared to the previous day [1] - Over 3,400 stocks in the market declined [1] Sector Performance - Leading sectors included carbon fiber, diversified finance, brain-computer interfaces, non-ferrous metals, CPO, wind power equipment, commercial aerospace, and humanoid robots [1] - Underperforming sectors were food and beverage, retail, batteries, chemicals, and influenza [1] ETF Performance - The non-ferrous metal sector saw gains, with the Dachen Fund Non-Ferrous Metal ETF rising by 2.9% [1] - The oil and gas sector performed well, with the Penghua Fund Oil and Gas ETF and the Jingshun Great Wall Fund Oil and Gas ETF increasing by 2% and 1.92%, respectively [1] - The AI sector showed signs of recovery, with the Kexin AI ETF and the Kexin Artificial Intelligence ETF rising by 2% [1] - The commercial aerospace sector continued its upward trend, with the Satellite ETF from Yifangda increasing by 1.7% [1] Declining ETFs - High-premium Hong Kong stock ETFs saw significant declines, with the Hang Seng ETF for Hong Kong Stock Connect hitting the limit down and the Hong Kong Stock Connect 50 ETF dropping by 7% [1] - The latest premium/discount rates for these ETFs were 5% and 0.27%, respectively [1] - The Hong Kong innovative drug sector declined, with the Hang Seng Innovative Drug ETF falling by 2% and the Hong Kong Stock Connect Innovative Drug ETF decreasing by 1.7% [1] - Power stocks experienced a pullback, with the Green Power ETF and Power ETF both declining by 1.6% [1]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a continuous pullback, attributed to three main factors: profit-taking by investors as the year-end approaches, liquidity tightening due to various monetary policy changes, and disappointing BD events for some companies [1][3][4]. Group 1: Market Dynamics - Investors are showing a strong tendency to realize profits as the year-end approaches, leading to a decline in market risk appetite [1][3]. - Liquidity in the Hong Kong market is tightening due to the Federal Reserve's interest rate cuts, rising expectations of interest rate hikes by the Bank of Japan, and a slowdown in southbound capital inflows [1][3]. - Some industry-specific BD events have underperformed expectations, negatively impacting market sentiment [1][3]. Group 2: Investment Opportunities - Despite the current market pullback, it is viewed as a short-term risk release that does not alter the narrative of accelerated nationalization, technological breakthroughs, and payment system innovations in the innovative drug sector [1][4]. - The Hang Seng Innovative Drug ETF (520500) has seen a net inflow of 235 million yuan over six consecutive trading days, reaching a historical high of 1.251 billion shares since its inception [4]. - The ETF has an average daily trading volume of 729 million yuan since Q4 2025, indicating substantial scale and liquidity [4]. Group 3: Future Outlook - Tianfeng Securities suggests that after a systematic asset value reassessment in 2025, the main theme for innovative drug investments will be the reduction of risks, leading to enhanced predictability and sustained competitiveness for companies [4]. - The National Medical Security Work Conference held on December 13, 2025, encouraged the inclusion of more reasonable medical expenses outside the basic medical insurance catalog into commercial health insurance, which is expected to boost investment in innovative drugs [4].

Core Insights - The global biotech landscape is undergoing a significant transformation, with China's innovative drugs projected to exceed $120 billion in licensing deals by October 2025, reflecting a growth of over 190% year-on-year. This indicates that Chinese biotech companies have evolved from mere imitators to a formidable force in the global innovation landscape [1]. Group 1: Global Biotech Industry Structure - The global innovative drug industry follows a "smile curve" structure, with CRO/CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) at the upstream, biotech companies as the innovative entities in the midstream, and large pharmaceutical companies (Big Pharma) managing commercialization at the downstream [2]. - Biotech companies are positioned in the high-value area of the smile curve, bearing the highest R&D risks while enjoying the greatest potential for innovation returns. They typically focus on early-stage drug development and often realize value through acquisitions or licensing agreements with larger pharmaceutical firms [4]. Group 2: Comparison of US and Chinese Biotech - The US biotech sector is currently facing severe survival challenges, with the Nasdaq Biotech Index under pressure and over 20 US biotech companies shutting down in 2025 due to funding issues. This is exacerbated by a cautious M&A strategy among multinational corporations (MNCs) amid tightening cash flows [7]. - In contrast, China's biotech sector is experiencing a surge in business development (BD) transactions, driven by its advantages in R&D efficiency, cost, and clinical resources. MNCs are increasingly attracted to Chinese biotech firms for their differentiated characteristics and high cost-effectiveness [9]. - Chinese biotech companies are focusing on differentiated innovation strategies, particularly in areas like antibody-drug conjugates (ADC) and bispecific antibodies, leading to a pipeline that surpasses that of the US, ranking first globally [10]. Group 3: Investment Opportunities - The growth trend of China's biotech industry is expected to be long-term and predictable, with upcoming international academic conferences likely to showcase more Chinese original drugs, offering substantial returns for investors [11]. - For ordinary investors, navigating the complexities of investing in innovative drug stocks can be challenging. Instead of chasing individual "blockbusters," it may be more prudent to consider ETFs that cover industry leaders, such as the Hang Seng Innovation Drug ETF, which tracks the Hang Seng Hong Kong Stock Connect Innovation Drug Index [11][12].

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with key indices showing significant gains, driven by positive news regarding leading companies and favorable market conditions [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.9%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.2%, both aiming for a third consecutive day of gains [1] - The performance of the innovative drug sector is supported by the anticipated interest rate cuts by the Federal Reserve, which have increased the probability of a 25 basis point cut in December from 40% to 80.9% [1] Group 2: Company Developments - Three-Six Pharmaceutical plans to spin off its Minoxidil brand, Mandi International, for a main board listing on the Hong Kong Stock Exchange [1] - The clinical trial application for ActRIIA/B antibody JMT206 injection by CSPC Pharmaceutical has been approved for obesity treatment [1] Group 3: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first ETF-tracked index with a 100% "purity" focus on leading innovative drug companies in Hong Kong [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of the 50 largest stocks in the pharmaceutical and health sector within the Stock Connect range, covering innovative drugs and medical devices [1] - The Hang Seng Innovative Drug ETF (159316) and the Hong Kong Stock Connect Medical ETF (513200) track these indices, providing investors with opportunities to capitalize on sector recovery [1]

Group 1: Mobile Games - The article discusses the growth and potential of the mobile gaming industry, highlighting its increasing popularity and revenue generation in recent years [1]. Group 2: ETF Grid Strategy - The ETF grid strategy focuses on several key ETFs, including the Hang Seng Innovative Drug ETF (520500.SH), which benefits from unprecedented domestic policy support for innovative drug development, such as the establishment of a "dual directory" multi-level payment system [3][4]. - The innovative drug pipeline in China has reached 7,041 projects, accounting for 29.5% of the global total, with a year-on-year growth of 15.1%, significantly outpacing the global average [4]. - The military ETF (512560.SH) is expected to benefit from a historical high defense budget of 1.81 trillion yuan in 2025, which represents a 7.2% increase, although it remains below 1.3% of GDP [7]. - The liquor ETF (512690.SH) has shown wide fluctuations in 2025, with an average daily amplitude of 1.77%, providing opportunities for frequent trading and profit capture [11]. - The Sci-Tech Chip Design ETF (588780.SH) focuses on the chip design sector, which is crucial for China's strategy to achieve technological self-reliance amid global competition [14].

Core Viewpoint - The development and scale competition of public ETF products are facing new regulatory requirements, with a focus on standardizing ETF naming conventions by March 31, 2026 [1][2]. Group 1: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges have issued revised guidelines requiring ETF names to include the fund manager's name and follow a specific naming structure: "core elements of investment target + ETF" [2][6]. - Existing ETFs must complete the renaming process by the specified deadline, prompting many public funds to respond actively [2][3]. Group 2: Market Response - Several public funds, including Dachen Fund and Penghua Fund, have already begun to change their ETF names in accordance with the new regulations, with Dachen Fund changing its ETF name to "深成长ETF大成" [2][3]. - Some funds have been proactive, with E-Fund and others adjusting multiple ETF names earlier in the year to align with the new naming rules [3][4]. Group 3: Strategic Considerations - Public funds are strategically timing their ETF name changes based on product performance and market potential, focusing on those with limited growth while reserving changes for high-potential ETFs until closer to the deadline [4][5]. - The trend shows that ETFs with names not including the fund manager's name have attracted more retail investor interest, especially in high-performing sectors [4][5]. Group 4: Enhanced Product Differentiation - The new naming conventions are expected to improve product differentiation in a crowded ETF market, making it easier for investors to identify and select products [6][7]. - The inclusion of the fund manager's name in ETF titles is anticipated to enhance investor decision-making efficiency and reduce information search costs [6][7].

Market Overview - The A-share market experienced a decline across major indices last week, with the Shanghai Composite Index, CSI 1000, and CSI 300 showing returns of -0.18%, -0.52%, and -1.08% respectively. In contrast, the STAR 50, ChiNext Index, and SME Board Index had poorer performances with returns of -3.85%, -3.01%, and -1.71% respectively [1] - In terms of industry performance, consumer services, textiles and apparel, and pharmaceuticals led with returns of 4.81%, 4.43%, and 3.29% respectively, while communication, electronics, and computers lagged with returns of -4.90%, -4.44%, and -3.72% respectively [1] Fund Flow - The ETF market saw a net inflow of 29.317 billion yuan last week, with stock ETFs contributing 17.352 billion yuan, QDII stock ETFs 5 billion yuan, commodity ETFs 5.957 billion yuan, money market fund ETFs 1.236 billion yuan, and bond ETFs experiencing a net outflow of 0.276 billion yuan [2] - Specific indices that saw significant net inflows include SGE Gold 9999 (5.573 billion yuan), STAR 50 (3.532 billion yuan), and ChiNext AI (2.300 billion yuan) [4] - Conversely, indices such as CSI A500 and CSI 300 experienced notable net outflows of 4.055 billion yuan and 2.640 billion yuan respectively [2][4] ETF Performance - The median weekly return for stock ETFs was -1.09%, with the CSI 50 ETF showing the highest median return of 0.02% among broad-based ETFs. Consumer ETFs had a median return of 2.10%, the highest among sectors [11] - Top-performing ETFs included the Hong Kong Stock Connect Innovative Drug ETF (10.92%), Hang Seng Innovative Drug ETF (10.80%), and Tourism ETF (9.30%) [12][14] - In contrast, ETFs such as 5G Communication ETF and Communication ETF saw declines of -7.03% and -6.89% respectively [16][18] New Fund Activity - A total of 56 funds were reported last week, an increase from the previous week, including one QDII and several thematic ETFs [20] - 25 new funds were established with a total issuance scale of 14.173 billion yuan, which is a decrease compared to the previous week [20] - 41 funds entered the issuance phase last week, with 33 more expected to begin issuance this week [21] Hot News - Several cross-border ETFs have been flagged for premium risks due to significant discrepancies between market trading prices and net asset values [22] - The "Southbound ETF" program expanded on November 10, adding six ETFs to the Hong Kong Stock Connect list, increasing the total number of products from 17 to 23 [23]